Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | BRAF | P15056 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | TDO2 | P48775 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28977413 | 0.88 | MAPT (0.51) | MAPTBRAFPOLBALDH1A1GFER | |
| SCHEMBL10792245 | 0.88 | TSHR (0.53) | MAPTBRAFPOLBALDH1A1GFER | |
| SCHEMBL30360235 | 0.88 | MAPT (0.51) | MAPTBRAFPOLBALDH1A1GFER | |
| SCHEMBL6817059 | 0.87 | MAPT (0.62) | MAPTBRAFPOLBALDH1A1GFER | |
| SCHEMBL29663729 | 0.86 | MAPT (0.69) | MAPTPOLBALDH1A1GFERMEN1 | |
| SCHEMBL26250508 | 0.85 | ALDH1A1 (0.58) | MAPTBRAFPOLBALDH1A1GFER | |
| SCHEMBL2090419 | 0.84 | ALDH1A1 (0.54) | MAPTPOLBALDH1A1GFERMEN1 | |
| SCHEMBL2090421 | 0.84 | ATM (0.58) | MAPTPOLBALDH1A1GFERMEN1 | |
| SCHEMBL2089843 | 0.84 | POLB (0.56) | MAPTPOLBALDH1A1GFERMEN1 | |
| SCHEMBL30360239 | 0.84 | MEN1 (0.53) | MAPTBRAFPOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109265451-B | Butyrylcholinesterase selective inhibitor and preparation method and application thereof | 中国药科大学 | 2022-07-15 | — | — | CN | disclosed |
| US-20220151991-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-05-19 | — | — | US | disclosed |
| EP-3438105-A1 | DIARYL- -LACTAM COMPOUND AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Fudan University (CN) | 2019-02-06 | — | — | EP | disclosed |
| CN-107778233-A | Preparation method of neuromuscular blocker intermediate | 四川科瑞德制药股份有限公司 | 2018-03-09 | — | — | CN | disclosed |
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| WO-2013008256-A1 | ONE POT ACYLATION OF AROMATIC AMINES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-01-17 | — | — | WO | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6245779-B1 | ANALGESICS; ANTIINFLAMMATORY AGENTS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2001-06-12 | — | — | US | disclosed |
| EP-0997463-A1 | NAPHTHYRIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2000-05-03 | — | — | EP | disclosed |
| WO-1998017662-A1 | PHENYL-SUBSTITUTED BICYCLIC HETEROCYCLYL DERIVATIVES AND THEIR USE | NOVARTIS AG (CH) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151991-A1 | SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION | GRB2, KRAS, HRAS | MAPT 3372/4885BRAF 11/4885POLB 3387/4885 |
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | PDE2A, PDE12, PDE5A | MAPT 2788/4885BRAF 3486/4885POLB 2095/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | MAPT 3082/4885BRAF 897/4885POLB 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.